Shen H - Search Results

1

Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease.

Tan SPF, Willemin ME, Snoeys J, Shen H, Rostami-Hodjegan A, Scotcher D, Galetin A. Tan SPF, et al. Among authors: shen h. Clin Pharmacol Ther. 2023 Dec;114(6):1243-1253. doi: 10.1002/cpt.3029. Epub 2023 Sep 8. Clin Pharmacol Ther. 2023. PMID: 37620246

2

Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation.

Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, Kallipatti S, Selvam S, Sukrutharaj S, Krishnamurthy P, Marathe P, Rodrigues AD. Shen H, et al. J Pharmacol Exp Ther. 2013 Mar;344(3):673-85. doi: 10.1124/jpet.112.200691. Epub 2013 Jan 7. J Pharmacol Exp Ther. 2013. PMID: 23297161

3

Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.

Shen H, Dai J, Liu T, Cheng Y, Chen W, Freeden C, Zhang Y, Humphreys WG, Marathe P, Lai Y. Shen H, et al. J Pharmacol Exp Ther. 2016 May;357(2):382-93. doi: 10.1124/jpet.116.232066. Epub 2016 Feb 23. J Pharmacol Exp Ther. 2016. PMID: 26907622

4

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A. Barnett S, et al. Among authors: shen h. Clin Pharmacol Ther. 2018 Sep;104(3):564-574. doi: 10.1002/cpt.983. Epub 2018 Jan 17. Clin Pharmacol Ther. 2018. PMID: 29243231 Free PMC article.

5

Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Humphreys WG, Galetin A. Barnett S, et al. Among authors: shen h. J Pharmacol Exp Ther. 2019 Jan;368(1):125-135. doi: 10.1124/jpet.118.253062. Epub 2018 Oct 12. J Pharmacol Exp Ther. 2019. PMID: 30314992

6

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.

Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, Galetin A, Giacomini KM, Hanna I, Kusuhara H, Lai Y, Rodrigues D, Sugiyama Y, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. Chu X, et al. Among authors: shen h. Clin Pharmacol Ther. 2018 Nov;104(5):836-864. doi: 10.1002/cpt.1216. Clin Pharmacol Ther. 2018. PMID: 30347454 Review.

7

Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects.

Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, Marathe P, Humphreys WG. Shen H, et al. J Pharmacol Exp Ther. 2019 Jan;368(1):136-145. doi: 10.1124/jpet.118.252643. Epub 2018 Oct 25. J Pharmacol Exp Ther. 2019. PMID: 30361237 Clinical Trial.

8

Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.

Zhang Y, Chen C, Chen SJ, Chen XQ, Shuster DJ, Puszczalo PD, Fancher RM, Yang Z, Sinz M, Shen H. Zhang Y, et al. Among authors: shen h. J Pharmacol Exp Ther. 2020 Oct;375(1):139-151. doi: 10.1124/jpet.120.000139. Epub 2020 Jul 27. J Pharmacol Exp Ther. 2020. PMID: 32719071

9

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability.

Takita H, Barnett S, Zhang Y, Ménochet K, Shen H, Ogungbenro K, Galetin A. Takita H, et al. Among authors: shen h. CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):137-147. doi: 10.1002/psp4.12582. Epub 2021 Jan 19. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33289952 Free PMC article.

10

Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.

Kikuchi R, Chothe PP, Chu X, Huth F, Ishida K, Ishiguro N, Jiang R, Shen H, Stahl SH, Varma MVS, Willemin ME, Morse BL. Kikuchi R, et al. Among authors: shen h. Clin Pharmacol Ther. 2023 Dec;114(6):1170-1183. doi: 10.1002/cpt.3062. Epub 2023 Oct 11. Clin Pharmacol Ther. 2023. PMID: 37750401 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,361 results

Search Page

Filters